跳轉至內容
Merck
全部照片(1)

重要文件

SML2259

Sigma-Aldrich

拉帕替尼

≥98% (HPLC)

同義詞:

拉帕替尼, GD 2016, GSK 572016, GW-572016, GW572016, N-(3-氯-4-((3-氟苯基)甲氧基)苯基)-6-(5-((2-甲基磺酰基乙基氨基)甲基)-2-呋喃基)喹唑啉-4-胺, N-(3-氯-4-((3-氟苯基)甲氧基)苯基)-6-(5-((((2-(甲基磺酰基)乙基)氨基)甲基)-2-呋喃基)-4-喹唑啉胺

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C29H26ClFN4O4S
CAS號碼:
分子量::
581.06
MDL號碼:
分類程式碼代碼:
12352200
NACRES:
NA.77

化驗

≥98% (HPLC)

形狀

powder

顏色

white to beige

溶解度

DMSO: 2 mg/mL, clear

儲存溫度

2-8°C

SMILES 字串

CS(=O)(CCNCC1=CC=C(C2=CC=C3N=CN=C(C3=C2)NC4=CC=C(C(Cl)=C4)OCC5=CC=CC(F)=C5)O1)=O

InChI

1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)

InChI 密鑰

BCFGMOOMADDAQU-UHFFFAOYSA-N

基因資訊

尋找類似的產品? 前往 產品比較指南

生化/生理作用

拉帕替尼(lapatinb)是针对表皮生长因子受体(EGFR/ErbB1)和人表皮生长因子受体2(HER2/ErbB2)的双酪氨酸激酶抑制剂。它与三磷酸腺苷(ATP)竞争酪氨酸激酶结构域上的结合位点。已有研究表明拉帕替尼参与乳腺、肺、外阴、胃和头颈癌等多种人癌细胞中的体外生长抑制和凋亡诱导。

象形圖

Exclamation mark

訊號詞

Warning

危險聲明

危險分類

Aquatic Chronic 4 - Eye Irrit. 2 - Lact.

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如果您需要協助,請聯絡 客戶支援

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Lapatinib in breast cancer
Bilancia D, et al.
Annals of Oncology, 18, vi26-vi30 (2007)
Sharad Verma et al.
PloS one, 13(2), e0190942-e0190942 (2018-02-02)
HER-2 belongs to the human epidermal growth factor receptor (HER) family. Via different signal transduction pathways, HER-2 regulates normal cell proliferation, survival, and differentiation. Recently, it was reported that MCF10A, BT474, and MDA-MB-231 cells bearing the HER2 K753E mutation were
Egle Avizienyte et al.
The Biochemical journal, 415(2), 197-206 (2008-07-01)
Recent clinical data indicates that the emergence of mutant drug-resistant kinase alleles may be particularly relevant for targeted kinase inhibitors. In order to explore how different classes of targeted therapies impact upon resistance mutations, we performed EGFR (epidermal-growth-factor receptor) resistance
Dongwei Zhang et al.
Molecular cancer therapeutics, 7(7), 1846-1850 (2008-07-23)
Epidermal growth factor receptor (EGFR/ErbB1) and HER2 (ErbB2/neu), members of the ErbB receptor tyrosine kinase family, are frequently overexpressed in breast cancer and are known to drive tumor growth and progression, making them promising targets for cancer therapy. Lapatinib is

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務